PolyPid Stock

PolyPid EBIT

The EBIT of PolyPid (PYPD) as of Jul 15, 2026 is -28.00 M USD. In the previous year, EBIT was -23.00 M USD — a change of 21.74% (lower).

EBIT

-28.00 MUSD

YoY

21.74%

Last updated:

In 2026, PolyPid's EBIT was -28.00 M USD, a 21.74% increase from the -23.00 M USD EBIT recorded in the previous year.

The PolyPid EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-28.00 base
Jan 1, 2025 (e)
-32.08 base
Jan 1, 2026 (e)
-33.10 base
Jan 1, 2027 (e)
-27.08 base
Jan 1, 2028 (e)
5.71 base
Jan 1, 2029 (e)
75.07 base
Jan 1, 2030 (e)
160.75 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 160.75
2029 est 75.07
2028 est 5.71
2027 est -27.08
2026 est -33.10
2025 est -32.08
2024 -28.00
2023 -23.00
2022 -38.89
2021 -43.15
2020 -26.27
2019 -18.56
2018 -18.36
2017 -13.80
2016 -10.26
2015 -8.57
2013 -3.58
2012 -1.79
Access this data via the Eulerpool API

PolyPid Revenue

PolyPid Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
0.00 USD
-28.00 M USD
-29.00 M USD
Jan 1, 2025 (e)
0.00 USD
-32.08 M USD
-35.49 M USD
Jan 1, 2026 (e)
0.00 USD
-33.10 M USD
-21.50 M USD
Jan 1, 2027 (e)
23.87 M USD
-27.08 M USD
-15.94 M USD
Jan 1, 2028 (e)
82.82 M USD
5.71 M USD
0.00 USD
Jan 1, 2029 (e)
164.73 M USD
75.07 M USD
33.08 M USD
Jan 1, 2030 (e)
263.36 M USD
160.75 M USD
70.23 M USD
Jan 1, 2031 (e)
58.14 M USD
0.00 USD
0.00 USD

PolyPid Margins

PolyPid stock margins

The PolyPid margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PolyPid. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PolyPid.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
-113.46 %
-66.80 %
Jan 1, 2028 (e)
0.00 %
6.90 %
0.00 %
Jan 1, 2029 (e)
0.00 %
45.57 %
20.08 %
Jan 1, 2030 (e)
0.00 %
61.04 %
26.67 %
Jan 1, 2031 (e)
0.00 %
0.00 %
0.00 %

PolyPid Stock analysis

What does PolyPid do? PolyPid Ltd is an innovative, emerging company in the field of biomedical technology based in Israel. The company was founded in 2008 and has since gained continuous recognition and growth. PolyPid's core business is the development and manufacturing of implantable polymer systems that contribute to wound healing. These polymer systems are specifically introduced into the affected area of the body and continuously release active substances to prevent infections and promote natural healing processes. PolyPid's business model is focused on effectively solving patients' problems. The company has developed a wide range of products and technologies that specifically target various medical applications. These include orthopedics, traumatology, urology, and gynecology. For orthopedics, PolyPid provides various products and technologies that can be used in knee and hip joint surgeries. These include antibiotic-releasing implants to prevent infections and resorbable bone fillers that allow for faster and more effective wound healing. In the field of traumatology, PolyPid manufactures polymer systems that are used in the treatment of bone fractures or other traumas. Here again, the polymer systems ensure continuous release of active substances to prevent infections and promote natural healing processes. PolyPid also offers innovative solutions for urology. Specifically, products are developed to combat urinary tract infections and promote faster wound healing after urological surgeries. For gynecology, PolyPid offers polymer systems that can be used particularly in the postoperative phase to prevent infections and achieve faster wound healing. PolyPid has earned an excellent reputation in the industry in recent years due to its consistent focus on innovation and quality. To continually improve their products, the company invests heavily in research and development and maintains close contact with medical institutions and professionals worldwide. PolyPid is an important partner in the field of biomedical technology and has already received numerous awards for its groundbreaking products and developments. Thanks to its focus on quality, reliability, and innovation, the company will continue to play a key role in the biomedical technology market. PolyPid is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing PolyPid's EBIT

PolyPid's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of PolyPid's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

PolyPid's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in PolyPid’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about PolyPid stock

EBIT of PolyPid is -28.00 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — PolyPid

All Key Metrics — PolyPid